#883: How to Legalize Medical Psychedelics in Your Country — Tania de Jong on The Playbook Behind Australia's World-First Breakthrough · The Tim Ferriss Show summary

Key takeaways

Persistence and strategic coalition-building are crucial for systemic change, especially in regulatory environments.
Public support can be a powerful force—thousands of community submissions helped sway policy decisions.
Leveraging expert voices and personal stories directly impacts policy and societal acceptance.
Addressing regulatory and cost barriers requires ongoing advocacy, data collection, and innovative solutions.
Pushing for access to psychedelic medicines involves resilience, timing, and knowing when to step back or try new approaches.
The importance of curiosity, compassion, and walking each other home in fostering societal healing and understanding.

Summary

The Catalyst and Early Inspiration for Psychedelic Advocacy

The episode begins with Tanya de Jong recounting the pivotal moment in 2015 when Michael Pollan’s article, "The Trip Treatment," sparked her interest in psychedelics and mental health. Her first psychedelic experience, with psilocybin in the Netherlands, was deeply transformative, taking about a year to fully integrate. Her journey was fueled by a desire to help others struggling with mental health issues, particularly through her charitable work and her connection with influential figures like Rick Doblin and Robin Carhart-Harris. This foundation led to the creation of Mind Medicine Australia, an organization dedicated to advancing psychedelic medicine.

Strategic Advocacy and Building a Grassroots Movement

Tanya emphasized the importance of persistence, strategic advocacy, and assembling a broad coalition of supporters, including clinicians, researchers, philanthropists, and families. A key tactic was leveraging public support—over 13,000 submissions favored rescheduling MDMA and psilocybin—showing tremendous community backing. The strategy included engaging high-profile scientists like David Nutt and Robin Carhart-Harris, organizing conferences, town halls, and presentations to regulators, and even utilizing personal talents such as singing to foster connections. The case studies and personal stories, like that of a woman whose husband died after not having access to psychedelic therapy, played a crucial role in influencing policy.

Regulatory Hurdles, Success, and the Australian Breakthrough

The journey involved multiple applications to Australia’s Therapeutic Goods Administration (TGA), facing initial rejections, and a tireless campaign of public education, clinician training, and lobbying. Key tactics included gathering and publishing public feedback, bringing respected researchers like David Nutt to speak directly to regulators, and organizing campaigns that culminated in Australia becoming the first country to reschedule MDMA and psilocybin for psychiatric use in 2023. The success was marked by an emotional moment when the rescheduling was announced, enabling clinical treatment of patients and opening a pathway for broader access.

Clinical Implementation, Costs, and Future Outlook

Post-rescheduling, the focus shifted to practical implementation: training clinicians, establishing clinics, and ensuring access. The cost analysis revealed that much of the expense lies in therapist time rather than the drugs themselves. Program costs range from $8,000 to $15,000 per treatment cycle, with potential for shorter-acting compounds to reduce costs further. The panel discussed the potential for group therapy, the importance of integrated care, and the need for ongoing data collection and evidence to maintain regulatory support. A major ongoing challenge is making these treatments affordable and accessible. Tanya advocates for continued persistence, innovation, and curiosity to expand global access.

The Power of Personal Resilience and a Call to Action

Throughout the episode, Tanya reflects on the personal and collective resilience required to push for major systemic change. She shares lessons learned, including when to persist and when to step back. Her narrative emphasizes the importance of asking questions, engaging with allies, and not being discouraged by setbacks. Listeners are encouraged to be curious, seek help, and take action—highlighting that most opportunities require asking and the courage to push boundaries. The episode closes with an uplifting message about the ripple effect of sharing curiosity and compassion to walk each other home.

Show notes

My guest today is Tania de Jong, co-founder of Mind Medicine Australia. Tania and her husband, Peter, helped lead the push that, in 2023, made Australia the first country in the world to allow MDMA and psilocybin to be prescribed for psychiatric conditions. I wanted to understand how the hell they helped make that happen and what the rest of the world can learn from it.

This episode is brought to you by:

ProLon science-backed Fasting Mimicking Diet that helps activate cellular renewal through fasting, while still eating nourishing meals: https://prolonlife.com/Tim
Momentous high-quality creatine for cognitive and muscular support: https://LiveMomentous.com/Tim
AG1 all-in-one nutritional supplement: DrinkAG1.com/Tim

Timestamps

[00:00:00] Intro from Tim.

[00:02:46] The article that changed Tania’s life.

[00:04:39] A first psychedelic experience—and the year it took to integrate it.

[00:10:17] Rick Doblin’s encouragement and the birth of Mind Medicine Australia.

[00:13:15] Turning regulatory rejection into a stronger application.

[00:20:48] Building a grassroots movement and training clinicians.

[00:23:23] Cold emails, scientific allies, and singing your way into the room.

[00:31:11] A week with Ram Dass: silence, singing, and an extraordinary LSD story.

[00:37:54] Bringing David Nutt—and a family’s devastating story—to the regulators.

[00:42:42] Dancing in the kitchen: Australia’s rescheduling breakthrough.

[00:43:40] From changing the rules to treating patients.

[00:48:18] Why Tim thinks MDMA is still underestimated.

[00:50:23] Integration beyond the session: therapy, nutrition, and exercise.

[00:52:29] Scaling access and collecting real-world evidence.

[00:58:13] Getting insurers, government agencies, and philanthropists on board.

[01:00:44] Syrian rue, psilocybin, and learning to let go of control.

[01:09:06] Dosing, expectations, and the pressure to take more.

[01:11:07] The promise of group therapy and shared integration.

[01:13:27] Hiring mistakes, personal attacks, and the resilience advocacy requires.

[01:22:43] Turning a window of change into lasting habits.

[01:24:56] Getting through to regulators and pushing for end-of-life access.

[01:27:32] The bureaucratic barriers that remain.

[01:30:43] What treatment costs—and why therapist time drives the bill.

[01:34:12] Could shorter-acting compounds make treatment more affordable?

[01:37:51] Ketamine, kratom, and the limits of “all natural.”

[01:42:19] The unexpected payoff from Tim’s ketamine experiment.

[01:46:51] What might come next for psychedelic access worldwide?

[01:48:10] Persistence versus pushiness—and knowing when to try another door.

[01:53:27] Supporting patients and training the next wave of clinicians.

[01:56:56] “Be curious”: exploring your inner world and walking each other home.

[02:00:40] The ripple effects of sharing your curiosity—and simply asking for help.

Timeline:

February 2, 2015: Michael Pollan publishes “The Trip Treatment” in The New Yorker, which is the article Tania credits with setting her journey in motion.
March 21, 2015: Tim releases his James Fadiman interview, “The Psychedelic Explorer’s Guide” (#66). Its show notes link to “The Trip Treatment.”
January 15, 2016: In 5-Bullet Friday, Tim announces support for Johns Hopkins’ psilocybin research and a personal commitment of at least $100,000 toward psychedelic research that year.
2016: Tania and Peter travel to the Netherlands for their first guided psilocybin experience. (Source)
2017–2019: UCSF conducts the psilocybin-assisted group-therapy study involving long-term AIDS survivors that Tim helped support. (Source)
May 6, 2018: Michael Pollan joins Tim for “Exploring the New Science of Psychedelics” (#313), discussing his forthcoming book (How to Change Your Mind).
May 15, 2018: Pollan’s How to Change Your Mind is published.
February 13, 2019: Tania and Peter publicly launch Mind Medicine Australia. (Source)
2020–2022: MMA applies to reschedule MDMA and psilocybin, faces rejection, and submits new applications in March 2022. (Source)
November 21, 2022: David Nutt presents to Australia’s medicines regulator, the TGA, supporting the case for therapeutic access. (Source)
February 3, 2023: The TGA announces restricted prescribing access to MDMA for PTSD and psilocybin for treatment-resistant depression, effective July 1, 2023. (Source)
January 2024: Patients begin receiving treatment under the new prescribing program. (Source)

*

For show notes and past guests on The Tim Ferriss Show, please visit tim.blog/podcast.

For deals from sponsors of The Tim Ferriss Show, please visit tim.blog/podcast-sponsors

Sign up for Tim’s email newsletter (5-Bullet Friday) at tim.blog/friday.

For transcripts of episodes, go to tim.blog/transcripts.

Discover Tim’s books: tim.blog/books.

Follow Tim:

Twitter: twitter.com/tferriss

Instagram: instagram.com/timferriss

YouTube: youtube.com/timferriss

Facebook: facebook.com/timferriss

LinkedIn: linkedin.com/in/timferriss

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

#883: How to Legalize Medical Psychedelics in Your Country — Tania de Jong on The Playbook Behind Australia's World-First Breakthrough